‘We Will Share Our Vaccine with the World.’ Inside the Chinese Biotech Firm Leading the Fight Against COVID-19
It was the Chinese philosopher Sun Tzu, and not Al Pacino in The Godfather Part 2, who first said, “Keep your friends close, and your enemies closer.” Yin Weidong, the CEO of Chinese biotech firm SinoVac, seems to have taken that advice to heart. On the desk in his office in Beijing are two plastic models of a virus—each blue core surrounded by red protein spikes. From the time it started spreading in the central Chinese city of Wuhan in late December, containing that virus has occupied virtually every waking moment for the scientist. The pandemic we now know as COVID-19 is rampaging across every continent. On the dozens of daily infection charts, broken down by nation and pasted floor to ceiling on Yin’s office wall, the numbers tell a horrifying story: 16 million infections and 640,000 deaths worldwide, including 146,000 American lives lost as of Monday. But if the enemy is close, so is a possible new friend. Yin’s desk is now also home to several small glass vials of SinoVac’s COVID-19 vaccine—dubbed CoronaVac—that began phase 3 trials involving 9,000 volunteers in Brazil last week. (A phase 1 trial involves small groups of patients to check a vaccine for negative side effects, and a phase two trial usually tests for a combination of safety and efficacy, while a phase 3 trial is like a phase 2 but involving many more participants.) “Looking at the data collected, I think we have more than an 80% chance of success,&rdqu...
I’m hopeful that some lasting changes for the better will come out of COVID-19 because that’s a common thread in human history.
Adapting to takeout mode, quick-serve model shows resilience during pandemic.
While other health care providers were reporting losses of hundreds of thousands of dollars a day as patients stayed away from hospitals, the cancer treatment provider reported its best financial year.
The coronavirus epidemic has hit buffets hard. Relying on sneeze guards and the good manners and hygiene of other diners is particularly problematic now.
Paul Kreth, co-owner and CEO of Shorty Small’s in Little Rock, told Arkansas Business that he and his team “just want to claim that we’re doing the best that we can possibly do” when it comes to protecting diners and the restaurant’s employees from the coronavirus.
Five months ago, state officials scrambled to prepare for a pandemic scenario in which the added caseload of COVID-19 patients overwhelmed the Arkansas network of hospitals.
By MICHEL ACCAD, MD With cases of COVID-19 either disappeared or rapidly diminishing from places like Wuhan, Italy, New York, and Sweden, many voices are speculating that herd immunity may have been reached in those areas and that it may be at hand in the remaining parts of the world that are still struggling with the pandemic. Lockdowns should end—or may not have been needed to begin with, they conclude. Adding plausibility to their speculation is the discovery of biological evidence suggesting that prior exposure to other coronaviruses may confer some degree of immunity against SARS-CoV...
More News: Biotechnology | Brazil Health | Cardiology | China Health | Coronavirus | COVID-19 | Government | Health | Heart | Indonesia Health | Middle East Health | Mumps | Mumps Vaccine | National Institutes of Health (NIH) | Orthopaedics | Outbreaks | Pandemics | SARS | Study | Turkey Health | Vaccines